Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma

Official Title

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma

Principal Investigator

Smith, Sonali

Brief Summary

This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in
combination with another study drug called ublituximab compared to TGR-1202 alone as a
possible treatment for Diffuse Large B-cell Lymphoma (DLBCL) that has come back or that has
not responded to standard treatment.